Pharming公司预期2025年产品销售额将达1.7亿至1.8亿欧元，总收入达1.8亿至1.9亿欧元；预计研发投资9千万至1亿欧元

财报速递

03/20

财务展望公司提供了以下关于未来业绩的指引： - 预计2025年产品销售额将增长至1.7亿至1.8亿欧元，推动整体商业业务的正现金流 - 预计2025年总收入将达到1.8亿至1.9亿欧元 - 预计2025年总研发投资为9千万至1亿欧元，这将部分通过补助资金和预期的研发税收抵免来抵消 - 持续严格关注现金管理，以支持足够的现金流应对关键节点；目标是2025年运营现金燃烧较当前下降50%以上

以上内容来自Benzinga Earnings专栏，原文如下：

Financial Outlook

The Company provides the following guidance on its future results:

• Product sales expected to grow to €170-180 million in 2025, driving positive cash-flows for the overall commercial business

• Total revenues expected to reach €180-190 million in 2025

• Total R&D investments expected between €90 - €100 million in 2025, which will be partially offset by grant fundings and anticipated R&D tax credits

• Continued stringent focus on cash management supporting sufficient cash runway to reach key inflection points; targeting more than 50% lower operating cash burn in 2025

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/news/1190541231"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190541231\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190541231?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-03-20 14:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190541231","market":"us","top_or_hot":-1,"title":"Pharming公司预期2025年产品销售额将达1.7亿至1.8亿欧元，总收入达1.8亿至1.9亿欧元；预计研发投资9千万至1亿欧元","media":"财报速递","content":"财务展望\n\n公司提供了以下关于未来业绩的指引：\n\n- 预计2025年产品销售额将增长至1.7亿至1.8亿欧元，推动整体商业业务的正现金流\n- 预计2025年总收入将达到1.8亿至1.9亿欧元\n- 预计2025年总研发投资为9千万至1亿欧元，这将部分通过补助资金和预期的研发税收抵免来抵消\n- 持续严格关注现金管理，以支持足够的现金流应对关键节点；目标是2025年运营现金燃烧较当前下降50%以上<br><br>以上内容来自Benzinga Earnings专栏，原文如下：<br><html><body><p>Financial Outlook </p><p>The Company provides the following guidance on its future results: </p><p>• Product sales expected to grow to €170-180 million in 2025, driving positive cash-flows for the overall commercial business </p><p>• Total revenues expected to reach €180-190 million in 2025 </p><p>• Total R&amp;D investments expected between €90 - €100 million in 2025, which will be partially offset by grant fundings and anticipated R&amp;D tax credits </p><p>• Continued stringent focus on cash management supporting sufficient cash runway to reach key inflection points; targeting more than 50% lower operating cash burn in 2025</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharming公司预期2025年产品销售额将达1.7亿至1.8亿欧元，总收入达1.8亿至1.9亿欧元；预计研发投资9千万至1亿欧元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharming公司预期2025年产品销售额将达1.7亿至1.8亿欧元，总收入达1.8亿至1.9亿欧元；预计研发投资9千万至1亿欧元\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1048278264\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/decf3d8a922fc5c1c1d787bf8b36173f);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">财报速递 </p>\n<p class=\"h-time\">2025-03-20 14:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n财务展望\n\n公司提供了以下关于未来业绩的指引：\n\n- 预计2025年产品销售额将增长至1.7亿至1.8亿欧元，推动整体商业业务的正现金流\n- 预计2025年总收入将达到1.8亿至1.9亿欧元\n- 预计2025年总研发投资为9千万至1亿欧元，这将部分通过补助资金和预期的研发税收抵免来抵消\n- 持续严格关注现金管理，以支持足够的现金流应对关键节点；目标是2025年运营现金燃烧较当前下降50%以上<br><br>以上内容来自Benzinga Earnings专栏，原文如下：<br><html><body><p>Financial Outlook </p><p>The Company provides the following guidance on its future results: </p><p>• Product sales expected to grow to €170-180 million in 2025, driving positive cash-flows for the overall commercial business </p><p>• Total revenues expected to reach €180-190 million in 2025 </p><p>• Total R&amp;D investments expected between €90 - €100 million in 2025, which will be partially offset by grant fundings and anticipated R&amp;D tax credits </p><p>• Continued stringent focus on cash management supporting sufficient cash runway to reach key inflection points; targeting more than 50% lower operating cash burn in 2025</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VALN","symbol_name":"Valneva SE","start_time":0,"source_url":"","article_id":"1190541231","we_media_id":"1048278264","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190541231","pubTimestamp":1742453669,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"财报速递","introduction":"每日财报追踪","home_visible":1,"id":"1048278264","head_image":"https://community-static.tradeup.com/news/decf3d8a922fc5c1c1d787bf8b36173f"},"summary":"公司提供了以下关于未来业绩的指引：。- 预计2025年产品销售额将增长至1.7亿至1.8亿欧元，推动整体商业业务的正现金流。- 预计2025年总收入将达到1.8亿至1.9亿欧元。- 预计2025年总研发投资为9千万至1亿欧元，这将部分通过补助资金和预期的研发税收抵免来抵消","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"VALN":"Valneva SE","TSS":"Total System Services"},"translate_title":"Pharming expects product sales to reach 170 million to 180 million euros in 2025, and total revenue to reach 180 million to 190 million euros; Estimated R&D investment of 90 million to 100 million euros","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSS":1,"VALN":0.9},"content_text":"财务展望\n\n公司提供了以下关于未来业绩的指引：\n\n- 预计2025年产品销售额将增长至1.7亿至1.8亿欧元，推动整体商业业务的正现金流\n- 预计2025年总收入将达到1.8亿至1.9亿欧元\n- 预计2025年总研发投资为9千万至1亿欧元，这将部分通过补助资金和预期的研发税收抵免来抵消\n- 持续严格关注现金管理，以支持足够的现金流应对关键节点；目标是2025年运营现金燃烧较当前下降50%以上以上内容来自Benzinga Earnings专栏，原文如下：Financial Outlook The Company provides the following guidance on its future results: • Product sales expected to grow to €170-180 million in 2025, driving positive cash-flows for the overall commercial business • Total revenues expected to reach €180-190 million in 2025 • Total R&D investments expected between €90 - €100 million in 2025, which will be partially offset by grant fundings and anticipated R&D tax credits • Continued stringent focus on cash management supporting sufficient cash runway to reach key inflection points; targeting more than 50% lower operating cash burn in 2025","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}